BACK TO TOP
KSE100
161,935.19
1277.70
(0.80%)
KSE100PR
50,882.96
401.48
(0.80%)
ALLSHR
97,989.63
780.92
(0.80%)
KSE30
49,083.13
357.19
(0.73%)
KMI30
231,590.56
1835.48
(0.80%)
BKTI
44,511.26
442.70
(1.00%)
OGTI
31,229.09
438.44
(1.42%)
KMIALLSHR
63,730.37
414.39
(0.65%)
PSXDIV20
71,938.16
473.35
(0.66%)
UPP9
55,397.18
345.58
(0.63%)
NITPGI
41,415.29
277.45
(0.67%)
NBPPGI
45,255.47
371.32
(0.83%)
MZNPI
28,394.03
259.49
(0.92%)
JSMFI
43,417.75
263.40
(0.61%)
ACI
23,374.91
141.47
(0.61%)
JSGBKTI
65,587.03
428.36
(0.66%)
HBLTTI
17,592.89
13-11-2025
0.07
(0.00%)
MII30
21,154.58
157.41
(0.75%)
BF Biosciences Limited
PHARMACEUTICALS
Rs.151.91
0.20
(0.13%)
1D
1M
6M
YTD
1Y
3Y
5Y
^ As of Fri, Nov 14, 2025 4:47 PM
REG
FUT
ODL
Open
151.71
High
153.16
Low
151.06
Volume
76,040
CIRCUIT BREAKER
136.54 — 166.88
DAY RANGE
151.06 — 153.16
52-WEEK RANGE ^
104.00 — 253.97
Ask Price
0.00
Ask Volume
0
Bid Price
0.00
Bid Volume
0
LDCP
151.71
VAR
15.50
HAIRCUT
22.50
P/E Ratio (TTM) **
27.67
1-Year Change * ^
47.87%
YTD Change * ^
-35.32%

No record found

No record found

Market data powered by capitalstake.com. Provided by PSX. ** Based on unconsolidated financials
  * Returns not adjusted for payouts
  ^The historical stock prices have been adjusted to reflect stock splits to ensure comparability over time.

Company Profile

BUSINESS DESCRIPTION

BF Biosciences Limited ("BFBL", "Company", or the "Issuer") was incorporated as an unlisted public limited company under the Companies Ordinance, 1984 (now Companies Act, 2017) in 2006, and operates within the pharmaceutical industry. BFBL is a 80%:20% joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina. The Company's core operations involve the import, manufacturing, marketing and distribution of pharmaceutical products.

KEY PEOPLE
Akhter Khalid WaheedCEO
Sebastian Martin FerrarassiChairperson
Abdur RehmanCompany Secretary
ADDRESS

197-A, The Mall, Rawalpindi, Pakistan

WEBSITE

www.bfbio.com

REGISTRAR

CDC Share Registrar Services Limited, CDC House, 99-B, Block-B, S.M.C.H.S, Main Shahrah Faisal, Karachi

AUDITOR

KPMG Taseer Hadi & Co. Chartered Accountants

Equity Profile

Market Cap (000's)
13,418,716.77
Shares
88,333,334
Free Float
26,500,000
Free Float
30.00%

Announcements

Financial Results
Board Meetings
Others
DateTitleDocument
Oct 30, 2025Transmission of Quarterly Financial Statements for the Period Ended 30-09-2025 View   PDF
Oct 27, 2025Financial Results for the Quarter Ended 2025-09-30 View   PDF
Oct 21, 2025Annual Progress Report for the Year Ended June 30, 2025 View   PDF
Oct 3, 2025Transmission of Annual Financial Statements for the Year Ended 30-06-2025 View   PDF
Sep 23, 2025Financial Results for the Year Ended 30-06-2025 View   PDF
DateTitleDocument
Oct 27, 2025Certified true copy of the resolutions passed in the Annual General Meeting of the Company View   PDF
Oct 17, 2025Board Meeting View   
Oct 3, 2025Notice of Annual General Meeting View   PDF
Oct 2, 2025Notice of Annual General Meeting prior to publication View   PDF
Sep 15, 2025Board Meeting View   
DateTitleDocument
Oct 14, 2025Material Information View   PDF
Oct 13, 2025Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View   
Apr 17, 2025Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View   
Jan 14, 2025Material Information View   PDF
Dec 24, 2024Clarification - Unusual Movement in Price of the Shares of the BF Biosciences Limited View   PDF

Financials

All numbers in thousands (000's) except EPS

Annual
Quarterly
20252024
Sales5,837,4663,658,720
Profit after Taxation447,147385,413
EPS5.526.09
Q1 2026Q3 2025Q2 2025Q1 2025
Sales2,432,2941,500,4691,327,2021,386,372
Profit after Taxation159,521124,52780,539115,273
EPS1.811.591.091.82
Data powered by Capital Stake. To provide comparable data, information might have been standardized. The data presented may therefore differ from issuer's annual report and 'as reported' data should be obtained directly from the source issuer. See the Capital Stake Terms of Use.

Ratios

202520242023
Gross Profit Margin (%)39.1941.89
Net Profit Margin (%)7.6610.53
EPS Growth (%)(9.36)
PEG(3.27)

Payouts

Financial Reports